CN1420882A - 取代的氧代氮杂杂环基化合物 - Google Patents

取代的氧代氮杂杂环基化合物 Download PDF

Info

Publication number
CN1420882A
CN1420882A CN00810877A CN00810877A CN1420882A CN 1420882 A CN1420882 A CN 1420882A CN 00810877 A CN00810877 A CN 00810877A CN 00810877 A CN00810877 A CN 00810877A CN 1420882 A CN1420882 A CN 1420882A
Authority
CN
China
Prior art keywords
ylmethyl
chloro
amino
piperazin
quinazolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN00810877A
Other languages
English (en)
Chinese (zh)
Inventor
W·R·厄温
M·R·贝克尔
Y·M·乔伊－斯勒德斯基
H·W·帕尔斯
W·何
S·M·康登
R·S·戴维斯
B·A·汉尼
A·P·斯帕达
C·J·伯恩斯
J·Z·江
A·李
M·R·梅尔斯
W·F·劳
G·B·波利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Aventis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc filed Critical Aventis Pharmaceuticals Inc
Publication of CN1420882A publication Critical patent/CN1420882A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Surgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Dental Preparations (AREA)
  • Steroid Compounds (AREA)
CN00810877A 1999-07-28 2000-07-26 取代的氧代氮杂杂环基化合物 Pending CN1420882A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36319699A 1999-07-28 1999-07-28
US09/363,196 1999-07-28

Publications (1)

Publication Number Publication Date
CN1420882A true CN1420882A (zh) 2003-05-28

Family

ID=23429232

Family Applications (1)

Application Number Title Priority Date Filing Date
CN00810877A Pending CN1420882A (zh) 1999-07-28 2000-07-26 取代的氧代氮杂杂环基化合物

Country Status (25)

Country Link
EP (1) EP1208097B1 (enExample)
JP (1) JP4829449B2 (enExample)
KR (1) KR20020087041A (enExample)
CN (1) CN1420882A (enExample)
AT (1) ATE423113T1 (enExample)
AU (1) AU773227B2 (enExample)
BG (1) BG106340A (enExample)
BR (1) BR0013179A (enExample)
CA (1) CA2382755A1 (enExample)
CR (1) CR6563A (enExample)
CZ (1) CZ2002323A3 (enExample)
DE (1) DE60041584D1 (enExample)
EE (1) EE200200045A (enExample)
HK (1) HK1054227A1 (enExample)
HR (1) HRP20020076A2 (enExample)
HU (1) HUP0203375A3 (enExample)
IL (2) IL147495A0 (enExample)
MX (1) MXPA02000888A (enExample)
NO (1) NO20020214L (enExample)
PL (1) PL354998A1 (enExample)
RU (1) RU2002105011A (enExample)
SK (1) SK1182002A3 (enExample)
TR (1) TR200200225T2 (enExample)
WO (1) WO2001007436A2 (enExample)
ZA (1) ZA200200543B (enExample)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104557928A (zh) * 2015-02-14 2015-04-29 佛山市赛维斯医药科技有限公司 一种含二环酰胺结构凝血因子Xa抑制剂、其制备方法及其用途
CN104557927A (zh) * 2015-02-14 2015-04-29 佛山市赛维斯医药科技有限公司 一种含二环酰胺结构的凝血因子Xa抑制剂及其用途
CN104557929A (zh) * 2015-02-14 2015-04-29 佛山市赛维斯医药科技有限公司 一类含二环酰胺结构的凝血因子Xa抑制剂及其用途
CN104557930A (zh) * 2015-02-14 2015-04-29 佛山市赛维斯医药科技有限公司 一种含二环酰胺结构凝血因子Xa抑制剂及其用途
CN104592227A (zh) * 2015-02-14 2015-05-06 佛山市赛维斯医药科技有限公司 一类含酰胺和卤代苯结构的FXa抑制剂、制备方法及其用途
CN104610259A (zh) * 2015-02-14 2015-05-13 佛山市赛维斯医药科技有限公司 含酰胺和氮杂环结构的FXa抑制剂、制备方法及其用途
CN104610260A (zh) * 2015-02-14 2015-05-13 佛山市赛维斯医药科技有限公司 一类含酰胺和氮杂环结构的FXa抑制剂、制备方法及其用途
CN104610258A (zh) * 2015-02-14 2015-05-13 佛山市赛维斯医药科技有限公司 一类含酰胺和甲氧苯结构的FXa抑制剂、制备方法及其用途
CN104610257A (zh) * 2015-02-14 2015-05-13 佛山市赛维斯医药科技有限公司 一类含酰胺结构的FXa抑制剂、制备方法及其用途
CN104650081A (zh) * 2015-02-14 2015-05-27 佛山市赛维斯医药科技有限公司 凝血因子Xa抑制剂、制备方法及其用途
CN104650082A (zh) * 2015-02-14 2015-05-27 佛山市赛维斯医药科技有限公司 一类凝血因子Xa抑制剂、制备方法及其用途
CN104672235A (zh) * 2015-02-14 2015-06-03 佛山市赛维斯医药科技有限公司 一类含双酰胺基和烷氧苯基结构的FXa抑制剂及其用途
CN104672236A (zh) * 2015-02-14 2015-06-03 佛山市赛维斯医药科技有限公司 一类含双酰胺基和卤代苯结构的FXa抑制剂及其用途
CN109991355A (zh) * 2019-04-12 2019-07-09 中国烟草总公司郑州烟草研究院 一种鉴定动物体内nab代谢产物的方法和评价nab在动物体内暴露风险的方法
CN110054619A (zh) * 2018-01-18 2019-07-26 西北农林科技大学 新型二酮哌嗪类组蛋白去乙酰化酶抑制剂

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA005893B1 (ru) 2000-03-21 2005-06-30 Смитклайн Бичам Корпорейшн Ингибиторы протеаз
EP1322643A1 (en) * 2000-09-29 2003-07-02 Millennium Pharmaceuticals, Inc. Piperazin-2-one amides as inhibitors of factor xa
HRP20030694A2 (en) * 2001-02-02 2005-04-30 Bristol-Myers Squibb Company Composition and antiviral activity of substitutedazaindoleoxoacetic piperazine derivatives
GB0112836D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0114005D0 (en) 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
GB0114004D0 (en) 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
EP1604982A1 (en) 2001-07-02 2005-12-14 AstraZeneca AB Intermediates for the preparation of piperidine derivatives useful as modulators of chemokine receptor activity
GB0120461D0 (en) 2001-08-22 2001-10-17 Astrazeneca Ab Novel compounds
AU2007229363B2 (en) * 2001-08-24 2009-06-04 University Of South Florida Piperazinone Compounds as Anti-Tumor and Anti-Cancer Agents and the Methods of Treatment
CA2458009C (en) * 2001-08-24 2011-08-16 Yale University Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment
GB0122503D0 (en) 2001-09-18 2001-11-07 Astrazeneca Ab Chemical compounds
EP1314733A1 (en) 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
WO2003075853A2 (en) 2002-03-08 2003-09-18 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
SE0200844D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
SE0200843D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
EP1502916A4 (en) 2002-04-16 2006-05-31 Teijin Ltd Piperidin derivatives with CCR3-antagonism
KR20040104596A (ko) 2002-04-25 2004-12-10 데이진 가부시키가이샤 Ｃｃｒ３ 길항 작용을 갖는 ４,４-２치환 피페리딘 유도체
TW200409637A (en) 2002-06-26 2004-06-16 Glaxo Group Ltd Compounds
AU2003272972A1 (en) * 2002-10-11 2004-05-04 Kowa Co., Ltd. Method of treatment for cancer
US7358268B2 (en) 2002-12-04 2008-04-15 Sanofi-Aventis Deutschland Gmbh Imidazole derivatives as factor Xa inhibitors
US7244748B2 (en) 2002-12-06 2007-07-17 Purdue Research Foundation Pyridines for treating injured mammalian nerve tissue
US8729107B2 (en) 2002-12-06 2014-05-20 Purdue Research Foundation Pyridines for treating injured mammalian nerve tissue
US7429581B2 (en) 2002-12-23 2008-09-30 Sanofi-Aventis Deutschland Gmbh Pyrazole-derivatives as factor Xa inhibitors
BRPI0408136A (pt) 2003-03-07 2006-03-01 Astellas Pharma Inc derivados heterocìclicos contendo nitrogênio tendo estirila 2,6-dissubstituìda
SE0300957D0 (sv) 2003-04-01 2003-04-01 Astrazeneca Ab Chemical compounds
US7223780B2 (en) 2003-05-19 2007-05-29 Sanofi-Aventis Deutschland Gmbh Triazole-derivatives as blood clotting enzyme factor Xa inhibitors
US7317027B2 (en) 2003-05-19 2008-01-08 Sanofi-Aventis Deutschland Gmbh Azaindole-derivatives as factor Xa inhibitors
EP1479675A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Indazole-derivatives as factor Xa inhibitors
US7741341B2 (en) 2003-05-19 2010-06-22 Sanofi-Aventis Deutschland Gmbh Benzimidazole-derivatives as factor Xa inhibitors
GB0315111D0 (en) * 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
RS20060035A (sr) 2003-07-22 2008-08-07 Arena Pharmaceuticals Inc., Derivati diaril i arilheteroaril uree kao modulatori receptora 5-ht2a serotonina korisni u profilaksi i lečenju poremećaja u vezi sa njima
SE0303180D0 (sv) 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
WO2006019497A2 (en) 2004-06-17 2006-02-23 Neurocrine Biosciences, Inc. Sleep-inducing compounds and methods related thereto
GB0420831D0 (en) 2004-09-17 2004-10-20 Glaxo Group Ltd Novel compounds
AU2006215080B2 (en) 2005-02-17 2011-03-10 Astellas Pharma Inc. Pyridyl non-aromatic nitrogenated heterocyclic-1-carboxylate ester derivative
WO2007008144A1 (en) * 2005-07-08 2007-01-18 Astrazeneca Ab Heterocyclic sulfonamide derivatives as inhibitors of factor xa
WO2007008146A1 (en) * 2005-07-08 2007-01-18 Astrazeneca Ab Heterocyclic sulfonamide derivatives as inhibitors of factor xa
JP2009501793A (ja) 2005-07-21 2009-01-22 アストラゼネカ・アクチエボラーグ 新規ピペリジン誘導体
US8143285B2 (en) * 2005-09-06 2012-03-27 Shionogi & Co., Ltd. Indolecarboxylic acid derivative having PGD2 receptor antagonistic activity
EP1926735A1 (en) 2005-09-22 2008-06-04 Incyte Corporation Tetracyclic inhibitors of janus kinases
EP1939175B1 (en) 2005-09-27 2017-03-01 Shionogi&Co., Ltd. Sulfonamide derivative having pgd2 receptor antagonistic activity
CN101336229B (zh) 2005-12-23 2012-06-13 西兰岛药物有限公司 改性的拟赖氨酸化合物
US7935706B2 (en) 2006-02-23 2011-05-03 Shionogi & Co., Ltd. Nitrogen-containing heterocycle derivatives substituted with cyclic group
JP2009532504A (ja) 2006-04-06 2009-09-10 グラクソ グループ リミテッド 抗菌薬
US8017612B2 (en) 2006-04-18 2011-09-13 Japan Tobacco Inc. Piperazine compound and use thereof as a HCV polymerase inhibitor
CN101528039A (zh) * 2006-05-26 2009-09-09 路易斯维尔大学研究基金会公司 巨噬细胞迁移抑制因子拮抗剂及其应用方法
EP1882688A1 (en) * 2006-07-25 2008-01-30 EPFL Ecole Polytechnique Fédérale de Lausanne Labelling of fusion proteins with synthetic probes
TWI415845B (zh) 2006-10-03 2013-11-21 Arena Pharm Inc 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物
US20080188545A1 (en) 2006-12-21 2008-08-07 Alimardanov Asaf R Synthesis of pyrrolidine compounds
EA019103B1 (ru) * 2007-03-20 2014-01-30 Кьюрис, Инк. Конденсированный аминопиридин в качестве ингибиторов hsp90
EP2190844B3 (en) 2007-08-15 2013-07-17 Arena Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
TW200944526A (en) 2008-04-22 2009-11-01 Vitae Pharmaceuticals Inc Carbamate and urea inhibitors of 11β-hydroxysteroid dehydrogenase 1
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
RS57110B1 (sr) 2008-10-28 2018-06-29 Arena Pharm Inc Sastavi modulatora 5-ht2a serotoninskog receptora korisni za tretiranje poremećaja povezanih sa njim
WO2011038234A2 (en) 2009-09-24 2011-03-31 University Of Louisville Research Foundation, Inc. Novel iodo pyrimidine derivatives useful for the treatment of macrophage migration inhibitory factor (mif)-implicated diseases and conditions
US9155790B2 (en) 2010-05-20 2015-10-13 University of Lousiville Research Foundation, Inc. Methods and compositions for modulating ocular damage
KR101251282B1 (ko) 2010-10-18 2013-04-10 서울대학교산학협력단 프로스타글란딘 합성을 억제하는 설폰아미드 유도체 및 이를 포함하는 약학적 조성물
CN102552274B (zh) * 2010-11-12 2013-10-23 姚雪彪 动点马达蛋白小分子抑制剂在抑制肿瘤细胞增殖中的应用
US8980924B2 (en) 2010-11-24 2015-03-17 The Trustees Of Columbia University In The City Of New York Non-retinoid RBP4 antagonist for treatment of age-related macular degeneration and stargardt disease
PL395470A1 (pl) 2011-06-29 2013-01-07 Adamed Spólka Z Ograniczona Odpowiedzialnoscia Sulfonamidowe pochodne amin alicyklicznych do leczenia chorób osrodkowego ukladu nerwowego
WO2013166037A1 (en) 2012-05-01 2013-11-07 The Trustees Of Columbia University In The City Of New York Non-retinoid antagonists for treatment of eye disorders
WO2014151936A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles, their preparation and use
WO2014151959A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
ES2705247T3 (es) 2013-03-14 2019-03-22 Univ Columbia 4-fenilpiperidinas, su preparación y uso
EP2968303B1 (en) 2013-03-14 2018-07-04 The Trustees of Columbia University in the City of New York Octahydrocyclopentapyrroles, their preparation and use
CN111393434B (zh) 2014-04-30 2022-11-04 哥伦比亚大学董事会 取代的4-苯基哌啶及其制备和用途
PL3174858T3 (pl) 2014-07-31 2019-10-31 Basf Se Sposób wytwarzania pirazoli
PE20180327A1 (es) 2015-05-11 2018-02-13 Basf Se Proceso para preparar 4-amino-piridazinas
AU2016276966A1 (en) 2015-06-12 2018-01-18 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of REM sleep behavior disorder
CR20170568A (es) 2015-06-26 2018-04-20 Takeda Pharmaceuticals Co Compuesto heterocíclico
EP3322415A4 (en) 2015-07-15 2019-03-13 Axovant Sciences GmbH DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR FOR PROPHYLAXIS AND TREATMENT OF HALLUCINATIONS RELATED TO A NEUROGENERATIVE DISEASE
JP6787913B2 (ja) * 2015-10-20 2020-11-18 武田薬品工業株式会社 複素環化合物
WO2018082964A1 (en) 2016-11-04 2018-05-11 Basf Se Process for the production of pyridazinyl-amides in a one-pot synthesis
JP7145875B2 (ja) 2017-04-18 2022-10-03 武田薬品工業株式会社 アセチルコリン受容体のモジュレーターとして有用な複素環化合物
US11324799B2 (en) 2017-05-05 2022-05-10 Zealand Pharma A/S Gap junction intercellular communication modulators and their use for the treatment of diabetic eye disease
BR112020020663A2 (pt) 2018-04-10 2021-01-12 Bayer Aktiengesellschaft Derivados de oxadiazolina
WO2022228387A1 (en) * 2021-04-26 2022-11-03 Fochon Biosciences, Ltd. Compounds as parp inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0684823A4 (en) * 1993-02-22 1997-07-09 Merck & Co Inc FIBRINOGEN RECEPTOR ANTAGONISTS.
US5849736A (en) * 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
US5612353A (en) * 1995-06-07 1997-03-18 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds
UA56197C2 (uk) * 1996-11-08 2003-05-15 Зенека Лімітед Гетероциклічні похідні
JP2002513412A (ja) * 1997-04-14 2002-05-08 シーオーアール セラピューティクス インコーポレイテッド 選択的Ｘａ因子阻害剤
CA2318351A1 (en) * 1997-12-26 1999-07-08 Hidemitsu Nishida Aromatic compounds having cyclic amino or salts thereof
UA59433C2 (uk) * 1998-01-27 2003-09-15 Авентіс Фармасьютікалс Продактс Інк. ЗАМІЩЕНІ ОКСОАЗАГЕТЕРОЦИКЛІЧНІ ІНГІБІТОРИ ФАКТОРА Хa ТА ПРОМІЖНІ СПОЛУКИ ДЛЯ ЇХ ОТРИМАННЯ
JP2000204081A (ja) * 1998-02-05 2000-07-25 Takeda Chem Ind Ltd スルホンアミド誘導体、その製造法及び用途
CN1290254A (zh) * 1998-02-05 2001-04-04 武田药品工业株式会社 氨磺酰衍生物及其制备和用途
WO2000032590A1 (en) * 1998-11-25 2000-06-08 Aventis Pharmaceuticals Products Inc. SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104650082A (zh) * 2015-02-14 2015-05-27 佛山市赛维斯医药科技有限公司 一类凝血因子Xa抑制剂、制备方法及其用途
CN104672235A (zh) * 2015-02-14 2015-06-03 佛山市赛维斯医药科技有限公司 一类含双酰胺基和烷氧苯基结构的FXa抑制剂及其用途
CN104557929A (zh) * 2015-02-14 2015-04-29 佛山市赛维斯医药科技有限公司 一类含二环酰胺结构的凝血因子Xa抑制剂及其用途
CN104557930A (zh) * 2015-02-14 2015-04-29 佛山市赛维斯医药科技有限公司 一种含二环酰胺结构凝血因子Xa抑制剂及其用途
CN104592227A (zh) * 2015-02-14 2015-05-06 佛山市赛维斯医药科技有限公司 一类含酰胺和卤代苯结构的FXa抑制剂、制备方法及其用途
CN104610259A (zh) * 2015-02-14 2015-05-13 佛山市赛维斯医药科技有限公司 含酰胺和氮杂环结构的FXa抑制剂、制备方法及其用途
CN104610260A (zh) * 2015-02-14 2015-05-13 佛山市赛维斯医药科技有限公司 一类含酰胺和氮杂环结构的FXa抑制剂、制备方法及其用途
CN104610258A (zh) * 2015-02-14 2015-05-13 佛山市赛维斯医药科技有限公司 一类含酰胺和甲氧苯结构的FXa抑制剂、制备方法及其用途
CN104610257A (zh) * 2015-02-14 2015-05-13 佛山市赛维斯医药科技有限公司 一类含酰胺结构的FXa抑制剂、制备方法及其用途
CN104650081A (zh) * 2015-02-14 2015-05-27 佛山市赛维斯医药科技有限公司 凝血因子Xa抑制剂、制备方法及其用途
CN104557927A (zh) * 2015-02-14 2015-04-29 佛山市赛维斯医药科技有限公司 一种含二环酰胺结构的凝血因子Xa抑制剂及其用途
CN104672236A (zh) * 2015-02-14 2015-06-03 佛山市赛维斯医药科技有限公司 一类含双酰胺基和卤代苯结构的FXa抑制剂及其用途
CN104557928A (zh) * 2015-02-14 2015-04-29 佛山市赛维斯医药科技有限公司 一种含二环酰胺结构凝血因子Xa抑制剂、其制备方法及其用途
CN104650082B (zh) * 2015-02-14 2016-06-01 佛山市赛维斯医药科技有限公司 一类凝血因子Xa抑制剂、制备方法及其用途
CN104557929B (zh) * 2015-02-14 2016-06-01 佛山市赛维斯医药科技有限公司 一类含二环酰胺结构的凝血因子Xa抑制剂及其用途
CN104650081B (zh) * 2015-02-14 2016-06-01 佛山市赛维斯医药科技有限公司 凝血因子Xa抑制剂、制备方法及其用途
CN104610257B (zh) * 2015-02-14 2016-06-01 佛山市赛维斯医药科技有限公司 一类含酰胺结构的FXa抑制剂、制备方法及其用途
CN104610259B (zh) * 2015-02-14 2016-06-01 佛山市赛维斯医药科技有限公司 含酰胺和氮杂环结构的FXa抑制剂、制备方法及其用途
CN104557928B (zh) * 2015-02-14 2016-08-24 佛山市赛维斯医药科技有限公司 一种含二环酰胺结构凝血因子Xa抑制剂、其制备方法及其用途
CN110054619A (zh) * 2018-01-18 2019-07-26 西北农林科技大学 新型二酮哌嗪类组蛋白去乙酰化酶抑制剂
CN109991355A (zh) * 2019-04-12 2019-07-09 中国烟草总公司郑州烟草研究院 一种鉴定动物体内nab代谢产物的方法和评价nab在动物体内暴露风险的方法

Also Published As

Publication number Publication date
EP1208097B1 (en) 2009-02-18
AU773227B2 (en) 2004-05-20
WO2001007436A2 (en) 2001-02-01
JP4829449B2 (ja) 2011-12-07
JP2003508353A (ja) 2003-03-04
AU6462800A (en) 2001-02-13
HUP0203375A3 (en) 2005-03-29
ZA200200543B (en) 2003-08-27
BG106340A (en) 2002-10-31
SK1182002A3 (en) 2002-11-06
CA2382755A1 (en) 2001-02-01
HUP0203375A2 (hu) 2002-12-28
HRP20020076A2 (en) 2003-12-31
WO2001007436A3 (en) 2001-08-23
DE60041584D1 (de) 2009-04-02
EP1208097A2 (en) 2002-05-29
NO20020214L (no) 2002-04-02
MXPA02000888A (es) 2002-07-30
ATE423113T1 (de) 2009-03-15
NO20020214D0 (no) 2002-01-15
PL354998A1 (en) 2004-03-22
KR20020087041A (ko) 2002-11-21
IL147495A0 (en) 2002-08-14
IL147495A (en) 2007-07-24
BR0013179A (pt) 2002-04-02
RU2002105011A (ru) 2004-01-20
CR6563A (es) 2008-11-25
TR200200225T2 (tr) 2002-06-21
EE200200045A (et) 2003-06-16
CZ2002323A3 (cs) 2002-05-15
HK1054227A1 (zh) 2003-11-21

Similar Documents

Publication Publication Date Title
CN1420882A (zh) 取代的氧代氮杂杂环基化合物
CN1291892A (zh) 取代的氧代氮杂杂环基因子Xa抑制剂
CN1221529C (zh) 取代的n－[(氨基亚氨基甲基或氨甲基)苯基]丙基酰胺
CN1293057C (zh) 乙二胺衍生物
US20110306589A1 (en) Nitrogen containing heteroaryl compounds
CN1894258A (zh) 可用作蛋白激酶抑制剂的组合物
CN1894234A (zh) 二肽基肽酶抑制剂
HK1052508A1 (zh) 作为凝血因子xa抑制剂的含氮杂双环
MXPA05002602A (es) Derivados de hidantoina y uso de los mismos como inhibidores de enzima convertidora de factor de necrosis tumoral-alfa.
CN1976907A (zh) 杂环酰胺化合物及其作为mmp－13抑制剂的用途
IL202827A (en) BENZO [d]AZEPINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM
CN1407985A (zh) 用作钾通道抑制剂的杂环二氢嘧啶
RS54945B1 (sr) Disupstituisani oktahidropirolo[3,4-c]piroli kao oreksin receptor modulatori
CN101952275A (zh) β-淀粉样蛋白的调节剂
CN1418882A (zh) 取代的磺酸n－[(氨基亚氨基甲基)苯基烷基]－氮杂环酰胺化合物
KR20160040321A (ko) 펩티드 데포르밀라제 억제제
CN1662521A (zh) 可用于治疗肥胖、ii型糖尿病和cns障碍的新化合物
US20240316047A1 (en) Inhibitors of rna helicase dhx9 and uses thereof
JP2003529531A (ja) 置換オキソアザへテロシクリルＸａ因子阻害剤
CN1950357A (zh) 用作tafia抑制剂的咪唑衍生物
CN1333766A (zh) 取代的(氨基亚氨基甲基或氨基甲基)苯并杂芳基化合物
HK1035489A (en) Substituted oxoazaheterocyclyl factor xa inhibitors
CN1711243A (zh) 用作嗜中性白细胞弹性蛋白酶抑制剂的2－吡啶酮衍生物
HK1099763A (en) New compounds useful for the treatment of obesity, type ii diabetes and cns disorders
HK1079525A (en) New compounds useful for the treatment of obesity, type ii diabetes and cns disorders

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1054227

Country of ref document: HK